DOCSLIB.ORG

Pharmaceutical Reference Substances and Impurities

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

Pharmaceutical reference substances and impurities 2006 / 2007 Contents Contents Introduction Introduction 3 Publications and subscriptions 5 United States Pharmacopeia and National Formulary 9 ATCC microbiological products 57 European Pharmacopoeia 55 ATCC microbiological products 108 Certified liquids for viscosity measurements 110 International commission on pharmaceutical enzymes 111 European Pharmacopoeia reagents 112 British Pharmacopoeia 117 ATCC microbiological products 130 Pharmacopée Française 132 Pharmacopoeia Helvetica 134 International Pharmacopeia 135 Institute of Dyes and Organic products 141 Refractive index CRMs 144 Pharmaceutical impurities 145 Background 147 Certificate of Analysis 148 List of products 151 High purity solvents 315 We are grateful to Medizin- und Apothekenhistorisches Museum Rhede e.V. for the supply of many of the photographic images in this catalogue. www.mam-rhede.de Edition 2006/2007 All your needs for pharmaceutical analysis - email [email protected] 1 Contents We constantly add new products to our range, so please call us to find out about new products and services and to make sure you are automatically kept up to date by subscribing to our free newsletter. Just send an email to [email protected] 2 All your needs for pharmaceutical analysis - email [email protected] Edition 2006/2007 List of LGC Promochem offices Introduction France • Germany • India • Italy • Poland • Spain • Sweden • UK List of LGC Promochem offices France Poland United Kingdom - Japan (Head office) LGC Promochem LGC Promochem - Korea 6, Rue Kastler ul. M. Konopnickiej 1 LGC Promochem - Macau B.P.76 Dziekanów Lesny Queens Road - Netherlands 67123 Molsheim 05-092 Lomianki Teddington - Romania France Poland Middlesex - Russia TW11 0LY Tel +33 (0)3 88 04 82 82 - Slovenia Tel +48 (0)22 751 31 40 United Kingdom Fax +33 (0)3 88 04 82 90 - Switzerland Fax +48 (0)22 751 58 45 Email [email protected] - Thailand Email [email protected] Tel +44 (0)20 8943 7565 - Turkey Fax +44 (0)20 8943 7554 Countries served Countries served Email - Algeria - Belorussia India [email protected] - Belgium - Lithuania - France LGC Promochem - Poland Countries served - Ivory Coast P.O. Box 8061 - Slovakia - Australia - Jordan No.142, 3rd Floor, 5th Cross - Ukraine - Brunei - Lebanon Rajmahal Vilas Extension - Canada - Libya Bangalore 560 080 Spain - Channel Islands - Madagascar India - Ireland LGC Promochem - Morocco - Kenya Tel +91 (0)80 2361 1256 C/Salvador Espriu 59, 2º planta - Senegal - Kuwait Fax +91 (0)80 2361 3859 08005 Barcelona - Syria - Malta Email [email protected] Spain - Tanzania - New Zealand - Tunisia Countries served Tel +34 93 308 4181 - Philippines - Bangladesh Fax +34 93 307 3612 - Saudi Arabia Germany - India Email [email protected] - South Africa - Malaysia - United Arab Emirates LGC Promochem Countries served - Nepal - United Kingdom Mercatorstrasse 51 - Andorra - Pakistan 46485 Wesel - Portugal - Spain Germany Italy - Latin America Tel +49 (0)281 9887 0 LGC Promochem s.r.l. Fax +49 (0)281 9887 199 Via Venezia, 23 Sweden Email [email protected] 20099 Sesto San Giovanni LGC Promochem Countries served Milan Box 1737 - Austria Italy SE-501 17 Borås - Bulgaria Tel +39 02 2412 6830 Sweden - China (Hong Kong, Singapore) Fax +39 02 2412 6831 - Croatia Tel +46 (0)33 20 90 60 Email [email protected] - Cyprus Fax +46 (0)33 20 90 79 - Czech Republic Countries served Email [email protected] - Egypt - Italy Countries served - Germany - Denmark - Greece - Estonia - Hungary - Finland - Iran - Iceland - Israel - Latvia - Norway - Sweden Your LGC Promochem account number Your contact at LGC Promochem is Name: Tel: Fax: www.lgcpromochem.com Email: For countries not listed above, please contact our head office. Introduction Introduction About LGC Promochem LGC Promochem is the leading reference materials supplier in Europe. Our relationships with the world’s leading pharmacopeias and their range of Chemical Reference Substances (CRS) and Reference Standards (RS), combined with in-house production of a wide variety of certified reference materials and pharmaceutical impurities, enable us to meet the often exacting needs of our customers. LGC Promochem’s network of offices across Europe and India and experience in reference materials distribution allow us to provide faster delivery, local technical support and assistance with import requirements. LGC Promochem's range of products also includes reference materials for clinical and forensic applications, phytochemicals, environmental analysis, determination of physical properties, and for food and beverage analysis. LGC Promochem is also the exclusive European distributor for ATCC cultures and bioproducts. For more information about our range of services or to receive any of our catalogues, please refer to our website www.lgcpromochem.com or contact your local office. About the catalogue The 2006/2007 edition of the LGC Promochem catalogue ‘Pharmaceutical reference substances and impurities’, replaces the ‘Pharmaceutical reference substances and impurities’ 2005/2006 edition and the three newsletter updates. The information provided in this catalogue as regards compendial articles is based on the ‘official’ pharmacopoeial lists and is correct at the time of print. Original descriptions and spellings used by the producers are retained. In some cases additional information has been included to make the lists more convenient to use. A regularly updated version of this catalogue is available from the LGC Promochem website at www.lgcpromochem.com, where pages can be reviewed and downloaded for printing. Pharmaceutical reference substances Certification The products described in this catalogue include pharmacopeial reference substances for use in pharmaceutical analysis. Pharmacopeial CRSs and RSs should be distinguished from certified reference materials (CRMs), which are produced in conformity with the ISO guides 30 to 35, and supplied with a detailed certification document. Pharmacopeial reference substances are produced for a specific purpose, and the manufacturers follow rigorous protocols to ensure the reference substance is fit for the intended purpose. The ‘certification’ processes follow the basic requirements of the relevant ISO REMCO guides, but are modified by the pharmacopoeias to reflect the particular demands of the associated pharmaceutical monograph. Details are given in the introduction to each section listing the various CRS collections in this catalogue. Shelf Life, storage and expiry dates Pharmacopeial CRSs and RSs should be purchased when required and not stored for a prolonged period. Pack sizes are designed to allow a limited number of replicate analyses, as required by Good Analytical Practice, but the opened pack should not be kept for future use. Please check all individual storage temperature requirements and note that the substances should be kept away from humidity and light (unless otherwise stated). Specific lot numbers or letters are allocated to all pharmacopeial reference substances, but no expiry dates are set. New lots are normally prepared well in advance of the expected "sell-out" of the current lot. When a substance is withdrawn from sale because the lot has depleted a final expiry date is given, by which any material from the outgoing lot held by users must be used. This means that for a period of time both lots are ‘official’. Lot information is provided by USP and EP in their literature and is available from LGC Promochem. If a material is withdrawn by the producer, then all stocks held by the users are no longer valid and have to be destroyed. Should this occur, LGC Promochem will inform all customers who have purchased the withdrawn substance. Please note that such a situation is outside LGC Promochem’s control and products are not refundable. Edition 2006/2007 All your needs for pharmaceutical analysis - email [email protected] 3 Pharmaceutical reference substances Impurity standards Impurities in a pharmaceutical substance can change the effects and side effects of a drug significantly. Therefore, it is important to have an accurate detection of impurities. The pharmaceutical monographs regulate the legal definition, the analysis and the limits of impurities of a given substance. An official range of impurity standards is available from the main pharmacopoeias where a CRS or RS is required in the monograph. Other impurity standards are listed in the ‘pharmaceutical impurities’ section of the catalogue. Controlled substances A number of the pharmaceutical substances, such as narcotics and tranquillisers, described in this catalogue are Controlled Substances in their country of origin and are marked ‘Controlled Substance’ against the product description. The purchase, possession and use of Controlled Substances are subject to national and international regulations designed to limit their abuse. It is the responsibility of the customer to obtain any authorisation necessary to both purchase and possess Controlled Substances, complying with the laws of the importing country, before ordering. Customers wishing to obtain Controlled Substances must contact their LGC Promochem sales office before ordering, and clarify with the sales specialists the relevant national requirements, the associated charges and consequential delivery times. All orders for Controlled Substances must be provided in writing and signed by an authorised person. The orders must be accompanied with the original import permit and/or possession
Recommended publications
  • This Fact Sheet Provides Information to Patients with Eczema and Their Carers. About Topical Corticosteroids How to Apply Topic

    This Fact Sheet Provides Information to Patients with Eczema and Their Carers. About Topical Corticosteroids How to Apply Topic

    This fact sheet provides information to patients with eczema and their carers. About topical corticosteroids You or your child’s doctor has prescribed a topical corticosteroid for the treatment of eczema. For treating eczema, corticosteroids are usually prepared in a cream or ointment and are applied topically (directly onto the skin). Topical corticosteroids work by reducing inflammation and helping to control an over-reactive response of the immune system at the site of eczema. They also tighten blood vessels, making less blood flow to the surface of the skin. Together, these effects help to manage the symptoms of eczema. There is a range of steroids that can be used to treat eczema, each with different strengths (potencies). On the next page, the potencies of some common steroids are shown, as well as the concentration that they are usually used in cream or ointment preparations. Using a moisturiser along with a steroid cream does not reduce the effect of the steroid. There are many misconceptions about the side effects of topical corticosteroids. However these treatments are very safe and patients are encouraged to follow the treatment regimen as advised by their doctor. How to apply topical corticosteroids How often should I apply? How much should I apply? Apply 1–2 times each day to the affected area Enough cream should be used so that the of skin according to your doctor’s instructions. entire affected area is covered. The cream can then be rubbed or massaged into the Once the steroid cream has been applied, inflamed skin. moisturisers can be used straight away if needed.
  • (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 De Juan Et Al

    (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 De Juan Et Al

    US 200601 10428A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 de Juan et al. (43) Pub. Date: May 25, 2006 (54) METHODS AND DEVICES FOR THE Publication Classification TREATMENT OF OCULAR CONDITIONS (51) Int. Cl. (76) Inventors: Eugene de Juan, LaCanada, CA (US); A6F 2/00 (2006.01) Signe E. Varner, Los Angeles, CA (52) U.S. Cl. .............................................................. 424/427 (US); Laurie R. Lawin, New Brighton, MN (US) (57) ABSTRACT Correspondence Address: Featured is a method for instilling one or more bioactive SCOTT PRIBNOW agents into ocular tissue within an eye of a patient for the Kagan Binder, PLLC treatment of an ocular condition, the method comprising Suite 200 concurrently using at least two of the following bioactive 221 Main Street North agent delivery methods (A)-(C): Stillwater, MN 55082 (US) (A) implanting a Sustained release delivery device com (21) Appl. No.: 11/175,850 prising one or more bioactive agents in a posterior region of the eye so that it delivers the one or more (22) Filed: Jul. 5, 2005 bioactive agents into the vitreous humor of the eye; (B) instilling (e.g., injecting or implanting) one or more Related U.S. Application Data bioactive agents Subretinally; and (60) Provisional application No. 60/585,236, filed on Jul. (C) instilling (e.g., injecting or delivering by ocular ion 2, 2004. Provisional application No. 60/669,701, filed tophoresis) one or more bioactive agents into the Vit on Apr. 8, 2005. reous humor of the eye. Patent Application Publication May 25, 2006 Sheet 1 of 22 US 2006/0110428A1 R 2 2 C.6 Fig.
  • (CD-P-PH/PHO) Report Classification/Justifica

    (CD-P-PH/PHO) Report Classification/Justifica

    COMMITTEE OF EXPERTS ON THE CLASSIFICATION OF MEDICINES AS REGARDS THEIR SUPPLY (CD-P-PH/PHO) Report classification/justification of medicines belonging to the ATC group D07A (Corticosteroids, Plain) Table of Contents Page INTRODUCTION 4 DISCLAIMER 6 GLOSSARY OF TERMS USED IN THIS DOCUMENT 7 ACTIVE SUBSTANCES Methylprednisolone (ATC: D07AA01) 8 Hydrocortisone (ATC: D07AA02) 9 Prednisolone (ATC: D07AA03) 11 Clobetasone (ATC: D07AB01) 13 Hydrocortisone butyrate (ATC: D07AB02) 16 Flumetasone (ATC: D07AB03) 18 Fluocortin (ATC: D07AB04) 21 Fluperolone (ATC: D07AB05) 22 Fluorometholone (ATC: D07AB06) 23 Fluprednidene (ATC: D07AB07) 24 Desonide (ATC: D07AB08) 25 Triamcinolone (ATC: D07AB09) 27 Alclometasone (ATC: D07AB10) 29 Hydrocortisone buteprate (ATC: D07AB11) 31 Dexamethasone (ATC: D07AB19) 32 Clocortolone (ATC: D07AB21) 34 Combinations of Corticosteroids (ATC: D07AB30) 35 Betamethasone (ATC: D07AC01) 36 Fluclorolone (ATC: D07AC02) 39 Desoximetasone (ATC: D07AC03) 40 Fluocinolone Acetonide (ATC: D07AC04) 43 Fluocortolone (ATC: D07AC05) 46 2 Diflucortolone (ATC: D07AC06) 47 Fludroxycortide (ATC: D07AC07) 50 Fluocinonide (ATC: D07AC08) 51 Budesonide (ATC: D07AC09) 54 Diflorasone (ATC: D07AC10) 55 Amcinonide (ATC: D07AC11) 56 Halometasone (ATC: D07AC12) 57 Mometasone (ATC: D07AC13) 58 Methylprednisolone Aceponate (ATC: D07AC14) 62 Beclometasone (ATC: D07AC15) 65 Hydrocortisone Aceponate (ATC: D07AC16) 68 Fluticasone (ATC: D07AC17) 69 Prednicarbate (ATC: D07AC18) 73 Difluprednate (ATC: D07AC19) 76 Ulobetasol (ATC: D07AC21) 77 Clobetasol (ATC: D07AD01) 78 Halcinonide (ATC: D07AD02) 81 LIST OF AUTHORS 82 3 INTRODUCTION The availability of medicines with or without a medical prescription has implications on patient safety, accessibility of medicines to patients and responsible management of healthcare expenditure. The decision on prescription status and related supply conditions is a core competency of national health authorities.
  • Penetration of Synthetic Corticosteroids Into Human Aqueous Humour

    Penetration of Synthetic Corticosteroids Into Human Aqueous Humour

    Eye (1990) 4, 526--530 Penetration of Synthetic Corticosteroids into Human Aqueous Humour C. N. 1. McGHEE,1.3 D. G. WATSON, 3 1. M. MIDGLEY, 3 M. 1. NOBLE, 2 G. N. DUTTON, z A. I. FERNl Glasgow Summary The penetration of prednisolone acetate (1%) and fluorometholone alcohol (0.1%) into human aqueous humour following topical application was determined using the very sensitive and specific technique of Gas Chromatography with Mass Spec­ trometry (GCMS). Prednisolone acetate afforded peak mean concentrations of 669.9 ng/ml within two hours and levels of 28.6 ng/ml in aqueous humour were detected almost 24 hours post application. The peak aqueous humour level of flu­ orometholone was S.lng/ml. The results are compared and contrasted with the absorption of dexamethasone alcohol (0.1%), betamethasone sodium phosphate (0.1 %) and prednisolone sodium phosphate (0.5%) into human aqueous humour. Topical corticosteroid preparations have been prednisolone acetate (1.0%) and fluorometh­ used widely in ophthalmology since the early alone alcohol (0.1 %) (preliminary results) 1960s and over the last 10 years the choice of into the aqueous humour of patients under­ preparations has become larger and more going elective cataract surgery. varied. Unfortunately, data on the intraocular penetration of these steroids in humans has SUbjects and Methods not paralleled the expansion in the number of Patients who were scheduled to undergo rou­ available preparations; indeed until recently, tine cataract surgery were recruited to the estimation of intraocular penetration has study and informed consent was obtained in been reliant upon extrapolation of data from all cases (n=88), Patients with corneal disease animal models (see Watson et ai., 1988, for or inflammatory ocular conditions which bibliography).
  • Clinical Policy: Topical Agents: Corticosteroids

    Clinical Policy: Topical Agents: Corticosteroids

    Clinical Policy: Topical Agents: Corticosteroids Reference Number: OH.PHAR.PPA.92 Effective Date: 01/01/2020 Revision Log Last Review Date: Line of Business: Medicaid See Important Reminder at the end of this policy for important regulatory and legal information. Description TOPICAL AGENTS: CORTICOSTEROIDS – LOW POTENCY NO PA REQUIRED “PREFERRED” PA REQUIRED “NON- PREFERRED” DESONIDE cream, ointment (generic of Desowen®) ALCLOMETASONE cream, ointment (generic of FLUOCINOLONE ACETONIDE 0.01% cream, solution Aclovate®) (generic of Synalar®) CAPEX® shampoo (fluocinolone acetonide) FLUOCINOLONE body oil, scalp oil (generic of Derma- DESONATE®gel (desonide) Smoothe/ FS®) DESONIDE lotion (generic of Desowen®) HYDROCORTISONE cream, lotion, ointment HYDROCORTISONE ACETATE WITH ALOE gel HYDROCORTISONE WITH UREA cream (generic of Carmol HC®) PANDEL® cream (hydrocortisone probutate) PEDIADERM HC® kit TOPICAL AGENTS: CORTICOSTEROIDS – MEDIUM POTENCY NO PA REQUIRED “PREFERRED” PA REQUIRED “NON--PREFERRED” BETAMETHASONE DIPROPIONATE-CALCIPOTRIENE BETAMETHASONE DIPROPIONATE lotion (generic of Ointment Diprolene®) BETAMETHASONE VALERATE cream, lotion (generic of CLOCORTOLONE PIVALATE (generic of Cloderm®) Valisone®) CORDRAN® tape (flurandrenolide) FLUTICASONE PROPIONATE cream, ointment (generic of DESOXIMETASONE cream, gel, ointment (generic of Cutivate®) Topicort®) MOMETASONE FUROATE cream, ointment, solution FLUOCINOLONE ACETONIDE 0.025% cream, ointment (generic of Elocon®) (generic of Synalar®) PREDNICARBATE cream (generic of Dermatop®) FLUTICASONE
  • Steroids Topical

    Steroids Topical

    Steroids, Topical Therapeutic Class Review (TCR) September 18, 2020 No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopying, recording, digital scanning, or via any information storage or retrieval system without the express written consent of Magellan Rx Management. All requests for permission should be mailed to: Magellan Rx Management Attention: Legal Department 6950 Columbia Gateway Drive Columbia, Maryland 21046 The materials contained herein represent the opinions of the collective authors and editors and should not be construed to be the official representation of any professional organization or group, any state Pharmacy and Therapeutics committee, any state Medicaid Agency, or any other clinical committee. This material is not intended to be relied upon as medical advice for specific medical cases and nothing contained herein should be relied upon by any patient, medical professional or layperson seeking information about a specific course of treatment for a specific medical condition. All readers of this material are responsible for independently obtaining medical advice and guidance from their own physician and/or other medical professional in regard to the best course of treatment for their specific medical condition. This publication, inclusive of all forms contained herein, is intended to be educational in nature and is intended to be used for informational purposes only. Send comments and suggestions to [email protected]. September
  • Estroquench™ Hormone Specific Formulation™

    Estroquench™ Hormone Specific Formulation™

    PRODUCT DATA DOUGLAS LABORATORIES® 08/2014 1 EstroQuench™ Hormone Specific Formulation™ DESCRIPTION EstroQuench™ is a Hormone Specific Formulation™ of ingredients that have documented anti-aromatase activity as well as androgenic adaptogens which support the function of endogenous aromatase inhibitors. Collectively these herbs promote minimal production and function of estrogens, while promoting testosterone function, including optimal sexual function in both genders. This formulation is designed to quench excessive production of estrogens and aberrant functions of them while supporting optimal function of androgens by maintaining the health of androgen producing glands.† Hormone Specific Formulation™ provided by Douglas Laboratories® and formulated by Dr. Joseph J Collins is created to support the optimal function of specific hormones through the use of hormone specific adaptogens, hormone specific agonists and hormone specific functional mimetics. This formulation may be used as part of a hormone health program with dietary and nutrient support. In addition, this formulation may be used by clinicians as an adjuvant to support optimal hormone health in patients who have been prescribed bioidentical hormone therapies. FUNCTIONS Aromatase (a cytochrome P450 enzyme {CYP19}) is the enzyme that controls the conversion of androgens to estrogens. More specifically, aromatase is the enzyme responsible for catalyzing the biosynthesis of androstenedione into estrone, and the biosynthesis of testosterone to estradiol. Estrogens include the broad range of aromatized hormones created form androgens. The specific attribute of estrogens that separate them from progestogens, androgens and corticoids is that estrogens are the only aromatized steroid hormones. Estradiol, the most potent endogenous estrogen, is biosynthesized by aromatization from androgens by aromatase (which is also called estrogen synthase).
  • Test Report Comprehensive Hormone Insights™

    Test Report Comprehensive Hormone Insights™

    698814 COMPREHENSIVE HORMONE INSIGHTS™ TEST REPORT Dr. Maximus, N.D. E: [email protected] Date of Collection: P: 403-241-4500 Time of Collection: F: 403-241-4501 Date of Receipt: www.rmalab.com Reported On: CHI Accession: 698814 Healthcare Professional Patient Age: Dr. Maximus, N.D. Date of Birth: Gender: Male F: Relevant Medications Biometrics Curcumin Height (in) : 73 Weight (lb) : 180 BMI : 24 Waist (in) : 35 Hip (in) : 41 CHI Accession: 698814 SUMMARY HMUS01 How to read the graphs LEGEND: 50 66 Sex Steroid Hormones 50 66 Middle third of 33 33 84 reference population Hormone Start of 83 100 80 100 highest 16 Percentile Precursors 16 Percentile third of Sum of Androgens Sum of Estrogens 50 66 reference 0 0 population (T, DHT, α+β androstanediol) Listed in Interp Guide 33 84 End of 100 16 lowest Percentile00 50 66 50 66 third of 33 33 84 reference 0 population Patient’s percentile rank 81 100 95 100 compared to reference 16 Percentile 16 Percentile population (see summary) DHEA + Metabolites Sum of Progesterone Metabolites 0 (DHEA + A + E) 0 α+β Pregnanediol Cortisol Melatonin Oxidative Stress Free Cortisol Profile (ng/mg) 100 50 66 50 66 33 84 33 84 80 64 100 0 100 16 Percentile 16 Percentile 60 6-sulfatoxy 8-Hydroxy-2- 0 Melatonin 0 deoxyguanosine 40 (Overnight) (Overnight) 20 6-sulfatoxymelatonin provides 8-hydroxy-2-deoxyguanosine is Cortisol/Creatinine (ng/mg) insight into melatonin levels. a marker of oxidative stress 0 Morning Dinner Bedtime A B C 50 66 Free cortisol Cortisol Metabolites 33 84 profile is used to provides a general Testosterone Cortisol assess diurnal assessment of 16 100 cortisol rhythm adrenal cortisol 16 Percentile Cortisol production Cortisol Metabolites 0 (α+β THF + THE) Testosterone Cortisol/Testosterone provides insight into relative catabolic (cortisol) and anabolic (testosterone) states.
  • Medication List

    Medication List

    Medication List Walgreens Plus™ members receive discounts on thousands of generic and brand-name medications included on this Medication List, which is divided into two sections, “Value Priced” Medications and “Discounted” Medications*. The price for a medication identified as “Value-Priced” is listed below: Get savings up to 85% off Cash Prices • 30-day-supply drugs cost $5 (tier 1), $10 (tier 2) or $15 (tier 3) on Atorvastatin (generic Lipitor) and • 90-day-supply drugs cost $10 (tier 1), $20 (tier 2) or $30 (tier 3) Rosuvastatin (generic Crestor) †† The Discounted Medications section lists the discounts offered to Walgreens Plus members on other generic and brand-name medications not included in the Value-Priced Medication section. The price for a medication is based on its tier and whether it is a 30-day or 90-day supply†. There may be an additional cost for quanities greater than those listed. This discount prescription pricing applies only to Walgreen Plus members on prescriptions purchased in select Walgreens stores that are not billed to insurance and/or used in combination with other health or pharmacy benefit programs. For further details, see your pharmacist or Walgreens.com/Plus. VALUE GENERICS NAPROXEN 250MG TAB 2 60 180 Antifungal NAPROXEN 500MG TAB 2 60 180 Quantity NAPROXEN 375MG TAB 2 60 180 Drug Name Tier 30 90 NAPROXEN DR 500MG TAB 3 60 180 FLUCONAZOLE 150MG TAB 2 1 3 TERBINAFINE 250MG TAB 2 30 90 Asthma Quantity Antiviral Drug Name Tier 30 90 Quantity ALBUTEROL 0.083% INH SOLN 25X3ML 2 75 225 Drug Name Tier 30 90 AMINOPHYLLINE
  • 2018 Apigenin Male Infertility (2).Pdf

    2018 Apigenin Male Infertility (2).Pdf

    Original Article Thai Journal of Pharmaceutical Sciences Apigenin and baicalin, each alone or in low-dose combination, attenuated chloroquine induced male infertility in adult rats Amira Akilah, Mohamed Balaha*, Mohamed-Nabeih Abd-El Rahman, Sabiha Hedya Department of Pharmacology, Faculty of Medicine, Tanta University, Postal No. 31527, El-Gish Street, Tanta, Egypt Corresponding Author: Department of Pharmacology, ABSTRACT Faculty of Medicine, Tanta University, Postal No. 31527, Introduction: Male infertility is a worldwide health problem, which accounts for about 50% of all El-Gish Street, Tanta, Egypt. cases of infertility and considered as the most common single defined cause of infertility. Recently, Tel.: +201284451952. E-mail: apigenin and baicalin exhibited a powerful antioxidant and antiapoptotic activities. Consequently, in [email protected]. the present study, we evaluated the possible protective effect of apigenin and baicalin, either alone or Edu.Eg (M. Balaha). in low-dose combination, on a rat model of male infertility, regarding for its effects on the hormonal assay, testicular weight, sperm parameters, oxidative-stress state, apoptosis, and histopathological Received: Mar 06, 2018 changes. Material and methods: 12-week-old adult male Wister rats received 10 mg/kg/d Accepted: May 08, 2018 chloroquine orally for 30 days to induce male infertility. Either apigenin (30 or 15 mg/kg/d), baicalin Published: July 10, 2018 (100 or 50 mg/kg/d) or a combination of 15 mg/kg/d apigenin and 50 mg/kg/d baicalin received daily
  • A New Robust Technique for Testing of Glucocorticosteroids in Dogs and Horses Terry E

    A New Robust Technique for Testing of Glucocorticosteroids in Dogs and Horses Terry E

    Iowa State University Capstones, Theses and Retrospective Theses and Dissertations Dissertations 2007 A new robust technique for testing of glucocorticosteroids in dogs and horses Terry E. Webster Iowa State University Follow this and additional works at: https://lib.dr.iastate.edu/rtd Part of the Veterinary Toxicology and Pharmacology Commons Recommended Citation Webster, Terry E., "A new robust technique for testing of glucocorticosteroids in dogs and horses" (2007). Retrospective Theses and Dissertations. 15029. https://lib.dr.iastate.edu/rtd/15029 This Thesis is brought to you for free and open access by the Iowa State University Capstones, Theses and Dissertations at Iowa State University Digital Repository. It has been accepted for inclusion in Retrospective Theses and Dissertations by an authorized administrator of Iowa State University Digital Repository. For more information, please contact [email protected]. A new robust technique for testing of glucocorticosteroids in dogs and horses by Terry E. Webster A thesis submitted to the graduate faculty in partial fulfillment of the requirements for the degree of MASTER OF SCIENCE Major: Toxicology Program o f Study Committee: Walter G. Hyde, Major Professor Steve Ensley Thomas Isenhart Iowa State University Ames, Iowa 2007 Copyright © Terry Edward Webster, 2007. All rights reserved UMI Number: 1446027 Copyright 2007 by Webster, Terry E. All rights reserved. UMI Microform 1446027 Copyright 2007 by ProQuest Information and Learning Company. All rights reserved. This microform edition is protected against unauthorized copying under Title 17, United States Code. ProQuest Information and Learning Company 300 North Zeeb Road P.O. Box 1346 Ann Arbor, MI 48106-1346 ii DEDICATION I want to dedicate this project to my wife, Jackie, and my children, Shauna, Luke and Jake for their patience and understanding without which this project would not have been possible.
  • Steroid Use in Prednisone Allergy Abby Shuck, Pharmd Candidate

    Steroid Use in Prednisone Allergy Abby Shuck, Pharmd Candidate

    Steroid Use in Prednisone Allergy Abby Shuck, PharmD candidate 2015 University of Findlay If a patient has an allergy to prednisone and methylprednisolone, what (if any) other corticosteroid can the patient use to avoid an allergic reaction? Corticosteroids very rarely cause allergic reactions in patients that receive them. Since corticosteroids are typically used to treat severe allergic reactions and anaphylaxis, it seems unlikely that these drugs could actually induce an allergic reaction of their own. However, between 0.5-5% of people have reported any sort of reaction to a corticosteroid that they have received.1 Corticosteroids can cause anything from minor skin irritations to full blown anaphylactic shock. Worsening of allergic symptoms during corticosteroid treatment may not always mean that the patient has failed treatment, although it may appear to be so.2,3 There are essentially four classes of corticosteroids: Class A, hydrocortisone-type, Class B, triamcinolone acetonide type, Class C, betamethasone type, and Class D, hydrocortisone-17-butyrate and clobetasone-17-butyrate type. Major* corticosteroids in Class A include cortisone, hydrocortisone, methylprednisolone, prednisolone, and prednisone. Major* corticosteroids in Class B include budesonide, fluocinolone, and triamcinolone. Major* corticosteroids in Class C include beclomethasone and dexamethasone. Finally, major* corticosteroids in Class D include betamethasone, fluticasone, and mometasone.4,5 Class D was later subdivided into Class D1 and D2 depending on the presence or 5,6 absence of a C16 methyl substitution and/or halogenation on C9 of the steroid B-ring. It is often hard to determine what exactly a patient is allergic to if they experience a reaction to a corticosteroid.